Impact of semaglutide on kidney, cardiovascular, and mortality outcomes by baseline BMI and weight loss in people with T2D and CKDdata from the FLOW trial [Abstract 1971-LB]
With proper oversight, adjustments can be made based on individual tolerability and efficacy, ensuring the administration plan is tailored to each person's unique needs and health status
Although rare, these risks should be discussed with your provider
Diarrhea is usually mild, but if it becomes severe, persistent, or causes dehydration, contact a doctor promptly
A recent real-world effectiveness study published in 2024 examined weight loss outcomes in patients using semaglutide 2.4 mg (Wegovy) and tirzepatide in routine clinical settings across the United States
Severe cases may require immediate action